Biotech firms have seen share prices slide since the election and announcements about cabinet nominations for the upcoming administration.
Pfizer has an attractive valuation with a forward P/E ratio of 8.8 and a price-to-book ratio of 1.54, plus long-term growth potential despite recent volatility. Given this evolving environment, now is the time for investors to consider the strengths and opportunities presented by Eli Lilly, Pfizer, and AstraZeneca. Here's why these companies remain compelling investment options:Of the three major vaccine firms listed above, Eli Lilly has performed the strongest over the last year. Shares of LLY have risen by nearly a quarter during that time and by a shocking 543% in the last five years.
However, the lowered guidance is a result of inventory management and in-process research and development costs rather than fundamental changes in the company's business.Pfizer produces of one of the most popular COVID-19 vaccines in the United States, and so it is perhaps no surprise that shares have pulled back 10.4% in the last month, particularly following the election.
Building on this momentum, the company raised its full-year guidance for total revenue and core EPS growth, reflecting confidence in its ongoing performance and future prospects. AstraZeneca's strong product lineup is matched by its pipeline, as analysts expect the company to release as many as two dozen new products by the end of the decade.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
ソース: Investingcom - 🏆 450. / 53 続きを読む »
ソース: Investingcom - 🏆 450. / 53 続きを読む »
ソース: Investingcom - 🏆 450. / 53 続きを読む »
ソース: Investingcom - 🏆 450. / 53 続きを読む »
ソース: Investingcom - 🏆 450. / 53 続きを読む »
ソース: Investingcom - 🏆 450. / 53 続きを読む »